BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1894176)

  • 21. [Residual Disease Status after Primary Cytoreductive Surgery in Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Carcinoma and Long-Term Progression-Free Survival].
    Otsuka I; Matsuura T
    Gan To Kagaku Ryoho; 2016 Dec; 43(13):2547-2551. PubMed ID: 28028263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.
    Piver MS; Lele SB; Marchetti DL; Baker TR; Tsukada Y; Emrich LJ
    J Clin Oncol; 1988 Jun; 6(6):983-9. PubMed ID: 3373267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
    Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
    Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Primary fallopian tube cancer].
    Böhme M; Donat H; Baumann D
    Zentralbl Gynakol; 1992; 114(5):244-8. PubMed ID: 1320802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of early-stage primary serous fallopian tube carcinomas and equivalent stage serous epithelial ovarian carcinomas.
    Horng HC; Lai CR; Chang WH; Wen KC; Chen YJ; Juang CM; Yen MS; Wang PH
    Taiwan J Obstet Gynecol; 2014 Dec; 53(4):547-51. PubMed ID: 25510699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Gynecol Oncol; 2012 Sep; 126(3):381-6. PubMed ID: 22609747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary fallopian tube carcinoma: a retrospective clinicopathologic study.
    Singhal P; Odunsi K; Rodabaugh K; Driscoll D; Lele S
    Eur J Gynaecol Oncol; 2006; 27(1):16-8. PubMed ID: 16550961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
    Schlappe BA; Mueller JJ; Zivanovic O; Gardner GJ; Long Roche K; Sonoda Y; Chi DS; O'Cearbhaill RE
    Gynecol Oncol; 2016 Jul; 142(1):13-18. PubMed ID: 27189456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
    Rothenberg ML; Ozols RF; Glatstein E; Steinberg SM; Reed E; Young RC
    J Clin Oncol; 1992 May; 10(5):727-34. PubMed ID: 1569445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
    J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients.
    Tangjitgamol S; See HT; Manusirivithaya S; Levenback CF; Gershenson DM; Kavanagh JJ
    Int J Gynecol Cancer; 2004; 14(5):804-14. PubMed ID: 15361188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination chemotherapy with etoposide, cisplatin, and doxorubicin in mixed müllerian tumors of the adnexa.
    Cass I; Resnik E; Chambers JT; Chambers SK; Carcangiu ML; Kohorn EI; Schwartz PE
    Gynecol Oncol; 1996 Jun; 61(3):309-14. PubMed ID: 8641607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-look laparotomy in the management of fallopian tube carcinoma.
    Cormio G; Gabriele A; Maneo A; Marzola M; Lissoni A; Mangioni C
    Acta Obstet Gynecol Scand; 1997 Apr; 76(4):369-72. PubMed ID: 9174434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Primary fallopian tube cancer--an Austrian multicenter study].
    Rosen A; Klein M; Lahousen M; Graf AH; Bartussek A; Vavra N; Medl M; Virrani N; Schröck A; Fuith F
    Geburtshilfe Frauenheilkd; 1993 May; 53(5):321-5. PubMed ID: 8514103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
    Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
    Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
    Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
    Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study.
    Randall ME; Barrett RJ; Spirtos NM; Chalas E; Homesley HD; Lentz SL; Hanna M
    Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):139-47. PubMed ID: 12118543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.